- Coordinator
- Infrafrontier Eric, Germany
- Runs
- 1 June 2024 to 31 May 2027
- Status
- Running
- EU funding
- €4.0m
- Total cost
- €5.0m
- Partners
- 20 organisations in 13 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101131669
What the project is doing
In the project's own words, from its summary on CORDIS.
In response to the HORIZON-INFRA-2023-DEV-01-03 call, INFRAPLUS aims to expand INFRAFRONTIER's capacity for human disease modelling, refine its service portfolio by reducing animal usage and developing alternative cellular models, and optimise the use of resources. INFRAPLUS seeks to achieve several objectives: Developing national node capacities and expertise for providing innovative in vivo, in vitro and preclinical services, developing novel model systems and services to meet the demands of existing and novel user communities, and reducing environmental impact.
To achieve these objectives, INFRAPLUS will focus on launching pilot services, refining new technologies, emphasising alternate cellular models, designing and implementing special training programmes and optimising resources for the entire consortium. The project includes a defined service development strategy supported by a strong IT and data management backbone and is built upon the needs of the scientific community.
Ultimately, INFRAPLUS will enhance and evolve INFRAFRONTIER's capacity for modelling human diseases and enable breakthrough research by providing researchers cutting-edge tools and services to respond to global biomedical challenges.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Infrafrontier Eric | Neuherberg | Germany | Coordinator |
| Veterinaermedizinische Universitaet Wien | Wien | Austria | Participant |
| The Hospital for Sick Children | Toronto | Canada | Associatedpartner |
| Ustav Molekularni Genetiky Av Cr V.v.i. | Praha 4 | Czechia | Participant |
| Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH | Neuherberg | Germany | Participant |
| Biomedcode Ellas Anonimi Eteria Epistimonikis Kai Texnologikis Erevnas Kai Emborikis Ekmetallefsis Epharmogon Iatrikis | Vari | Greece | Participant |
| Erevnitiko Kentro Vioiatrikon Epistimon Alexandros Flemingk | Vari-Athens | Greece | Participant |
| Agencia Estatal Consejo Superior De Investigaciones Cientificas | Madrid | Spain | Participant |
| Universitat Autonoma De Barcelona | Cerdanyola Del Valles | Spain | Participant |
| Finnadvance Oy | Helsinki | Finland | Participant |
| Oulun Yliopisto | Oulu | Finland | Participant |
| Centre Europeen De Recherche En Biologie Et En Medecine | Illkirch Cedex | France | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Associatedpartner |
| Consiglio Nazionale Delle Ricerche | Roma | Italy | Participant |
| Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | Amsterdam | Netherlands | Participant |
| Fundacao Calouste Gulbenkian | Lisboa | Portugal | Participant |
| Fundacao Gimm - Gulbenkian Institute for Molecular Medicine | Lisboa | Portugal | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| United Kingdom Research and Innovation | Swindon | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI